Introduction {#sec1}
============

Bloodstream infection (BSI) is a severe and frequent complication among immunocompromised individuals \[[@ref1], [@ref2]\]. In paediatric oncology, it is known that BSI increases the chance of death during cancer treatment. In a multicentre study in New York of 4500 children, the probability of death was almost seven times higher in the group of patients with BSI compared to that without BSI (95% CI 3.02--16.00; *P* \< 0.05) \[[@ref3]\].

The outcome of BSI in patients with cancer is influenced by the type of underlying disease. A trend towards higher BSI severity and mortality in paediatric patients with haematological malignancies (HM) compared to those with solid tumours (ST) has been described previously \[[@ref4]\]. Better knowledge about the specific characteristics of BSI occurrence in children with different types of cancer could improve the clinical management of these patients. The aim of the present study was to describe and compare epidemiological, clinical and microbiological characteristics of BSI episodes, and the mortality associated with BSI, among paediatric patients with HM and ST admitted to a cancer referral hospital in a large urban centre in Brazil.

Methods {#sec2}
=======

Study design {#sec2-1}
------------

Patients were prospectively included in this cohort from a referral hospital for cancer prevention and treatment in Rio de Janeiro, Brazil between 1 October 2012 and 30 November 2015. All patients aged 18 years or less who had been admitted to the institution with a diagnosis of both cancer and BSI were eligible for inclusion into the study. Data from the first BSI episode identified in each child admitted during the study period were included.

Case detection and data collection {#sec2-2}
----------------------------------

The BSI episodes were prospectively identified by daily laboratory-based surveillance in patients with a positive blood culture. The following data were collected for 30 days before and 30 days after the date of BSI diagnosis (date when the first positive blood sample was obtained): (i) *demographic characteristics*: date of birth, gender, home address; (ii) *oncological disease and immunosuppressive conditions*: type of cancer, stage of oncological disease, bed confinement, radiotherapy or chemotherapy in the previous 30 days, absolute neutrophil count (ANC), corticosteroid use (dose \> 20 mg/day prednisone or equivalent for more than 7 days), invasive device use (such as vascular catheters, mechanical ventilation, parenteral nutrition, renal replacement therapy) at the moment or up to 72 h before the BSI, surgery, antibiotic use in the previous 30 days; and (iii) *BSI episodes*: microorganism species identified and their antimicrobial susceptibility, type of BSI (laboratory-confirmed or secondary): primary (without a clinically defined focus) or secondary (related to another focus of infection) or related to bacterial translocation from the gastrointestinal tract in patients with severe mucositis, C-reactive protein serum level on the date of BSI diagnosis or on the following day, indication for intensive care due to the BSI episode (initiation of life support measures, such as haemodynamic monitoring, oxygen therapy, mechanical ventilation and vasoactive amines), date and type of antibiotic administered for BSI treatment, clinical outcome and date (7-day death, 30-day death), final outcome during the hospitalisation and date of discharge or death.

Definitions {#sec3}
===========

The definitions of laboratory-confirmed BSI (LCBI), central line-associated BSI (CLABSI), mucosal barrier injury BSI (MBIBSI), primary BSI (PBSI) and secondary BSI (SBSI) were in accordance with The Centers for Disease Control and Prevention (CDC) recommendations \[[@ref5], [@ref6]\]. BSI following peripheral intravenous catheter use, arteriovenous fistula and/or endocarditis was defined as PBSI. Antimicrobial-resistant pathogens were defined according to resistance to specific antimicrobial agents as previously described \[[@ref7], [@ref8]\]: methicillin-resistant *Staphylococcus aureus* (MRSA); vancomycin-resistant *Enterococcus* spp.; penicillin-resistant *Streptococcus* spp.; enteric Gram-negative bacilli (EGNB) resistant to third or fourth generation cephalosporins and EGNB and non-fermentative Gram-negative bacilli resistant to carbapenems. The following criteria were used to define the appropriate antibiotic therapy: (i) the microorganism isolated from blood culture must be susceptible to at least one of the antibiotics used for the treatment and (ii) antibiotic therapy should be initiated within 24 h after BSI is suspected. De-escalation of antibiotic therapy occurred when a narrow-spectrum antibiotic was substituted for a broad-spectrum drug. Oncological disease stages were defined as: (i) disease under treatment if the child was undergoing first-line of treatment for oncological disease and had a possibility of being cured; (ii) disease under control if the cancer was under control or was cured after a specific treatment; and (iii) disease without a curative plan if the child was classified as a patient under palliative care or end-of-life care. This classification was based on medical records completed by the patient\'s treating physician. Neutropenia was defined as ANC \< 0.5 × 109/L and severe neutropenia as \<0.1 × 109/L or \<0.5 × 109/L for more than 7 days \[[@ref9]\]. Informal settlements were defined as census tracts with at least 51 houses built on illegally occupied land, with construction outside of an existing municipality or with precarious access to essential public services \[[@ref10]\].

Infection investigation and microbiological procedures {#sec3-1}
------------------------------------------------------

Two peripheral blood samples were obtained from at least two different venipuncture sites in each patient, as recommended by the Infection Control Division of the hospital. When long-term catheter-associated infection was suspected, an additional blood sample was collected from the suspected vascular device at the same time the peripheral blood sample was drawn. Each blood sample was placed into a separate culture bottle (BD BACTEC Lytic/10 Anaerobic/F, BACTEC plus Aerobic/F and BACTEC MYCO/F Lytic; Becton, Dickinson and Company; Maryland USA). Microorganism growth was detected by the BACTEC® 9240 system (Becton Dickinson). The identification of different species was performed by the Vitek2® automated system (BioMérieux), API 20, API Staph and rapid ID 32 Strep (BioMérieux®). Testing for antibiotic susceptibility was performed with Vitek2® and antibiotic gradient tests (BioMérieux), and interpreted in accordance with the Clinical and Laboratory Standards Institute recommendations \[[@ref11], [@ref12]\].

Statistical analysis {#sec3-2}
--------------------

Proportions and median values were reported for categorical and continuous variables, respectively. The *χ*^2^ or Fisher\'s exact tests were used as appropriate for comparison of categorical variables and Student\'s *t*-tests or Mann--Whitney test for comparison of continuous variables. Epidemiological, clinical and microbiological data were compared among children with ST and HM. A *P* value of \<0.05 was considered statistically significant. Data were collected using Magpi® Advanced Mobile Data Collection and analysed using the Stata11.0 statistical software program (Stata Corp LP, College Station, Texas).

Results {#sec4}
=======

Characteristics of the children {#sec4-1}
-------------------------------

During the study, 210 episodes of BSI in children with ST (*n* = 153) and HM (*n* = 57) were identified. Most (96.7%) of the children were older than 1 year of age, were being treated as 'cancer under control' (82.8%), were using vascular devices (95.2%) and had used antibiotics (66.7%) and chemotherapy (71.9%) within 30 days prior to a BSI episode.

The number of children aged 7 years or over was significantly higher in those with HM (63.2% *vs.* 45.1%; *P* = 0.03). The frequency of use of corticosteroids (50.3% *vs.* 68.4%, *P* = 0.02), antibiotics (62.7% *vs.* 77.2%; *P* = 0.05) and chemotherapy (67.3% *vs.* 84.2%; *P* = 0.01) within the 30 days before BSI diagnosis, and neutropenia (21.6% *vs.* 54.4%; *P* \< 0.001) and mucositis (12.4% *vs.* 29.8%; *P* \< 0.001) at the moment of the BSI episode, were significantly higher in patients with HM. Surgical procedures (7.2% *vs.* 0%; *P* = 0.03) and bed confinement (41.8% *vs.* 15.8%; *P* \< 0.001) in the 30 days before BSI, as well as mechanical ventilation (12.4% *vs.* 1.8%; *P* = 0.01) up to 72 h before the BSI, were more frequent in children with ST. The frequency of use of temporary (32.4% *vs.*14.5%; *P* = 0.01) and implanted vascular lines (39.3% *vs.* 5.4%; *P* \< 0.01) at the time of the BSI was significantly higher in children with ST than with HM while the frequency of tunnelled line (28.3% *vs.*81.8%; *P* = 0.01) use was significantly higher in children with HM as compared to ST. The characteristics of the children stratified by type of cancer are detailed in [Tables 1](#tab01){ref-type="table"} and [2](#tab02){ref-type="table"} Table 1.Characteristics of 210 patients with bloodstream infection stratified by type of paediatric cancerVariable, *n* (%)^a^Solid tumour (*n* = 153)Haematological malignancy (*n* = 57)*P* valueGender, male85 (55.6)36 (63.2)0.35Age, median (range)7 (0--18)10 (0--18)0.06A year or less5 (3.3)2 (3.5)0.99More than a year and ⩽7 years79 (51.6)19 (33.3)0.02More than 7 years69 (45.1)36 (63.2)0.03Housing in informal cluster^b^25 (16.3)10 (17.5)0.67Status of cancerUnder control7 (4.6)1 (1.8)0.68Under treatment123 (80.4)51 (89.5)0.15Without curative plan23 (15.0)5 (8.8)0.26Neutropenia^c^33 (21.6)31 (54.4)\<0.01Severe neutropenia^d^21 (13.7)20 (35.1)\<0.01Mucositis19 (12.4)17 (29.8)\<0.01Presence within 30 days before BSIChemotherapy103 (67.3)48 (84.2)0.01Radiotherapy16 (10.5)2 (3.5)0.16Antibiotic therapy96 (62.7)44 (77.2)0.05Use of corticosteroids77 (50.3)39 (68.4)0.02Bed confinement64 (41.8)9 (15.8)\<0.01Surgical procedure11 (7.2)00.03Presence at the time of BSIMechanical ventilation19 (12.4)1 (1.8)0.01Vascular device145 (94.8)55 (96.5)0.73Temporary line47 (32.4)8 (14.5)0.01Implanted line57 (39.3)3 (5.4)\<0.01Tunnelled line41 (28.3)45 (81.8)\<0.01Haemodialysis1 (0.7)1 (1.8)0.47[^1][^2][^3][^4][^5] Table 2.Types of solid tumours and haematological malignancies in 210 patients with bloodstream infectionType of tumourNumberFrequency (%)Solid tumour153Primary brain tumours23(15)Neuroblastoma22(14.3)Osteosarcoma21(13.7)Rhabdomyosarcoma13(8.5)PNET^a^12(7.8)Retinoblastoma10(6.5)Meduloblastoma9(5.9)Other tumours^b^43(28.1)Haematological malignancy57Acute lymphoblastic leukaemia23(40.3)Acute myeloid leukaemia11(19.3)Non-Hodgkin lymphoma18(31.6)Hodgkin lymphoma3(5.3)Non-classified lymphomas and leukaemias2(3.5)[^6][^7]

Characteristics of the BSI episodes {#sec4-2}
-----------------------------------

LCBSI (84.9%) was the most frequent type of infection, mainly CLABSI (52.9%). The frequency of temporary CLABSI was significantly higher in children with ST than with HM (25.5% *vs.* 10.5%; *P* = 0.02). Permanent CLABSI due to tunnelled catheter (59.6% *vs.* 20.9%; *P* \< 0.01) and implanted catheter (30.7% *vs.* 3.5%; *P* \< 0.01) were significantly more frequent in patients with HM and ST than with ST and HM, respectively. The frequency of BSI associated with mucosal barrier injury (MBIBSI; 12.3% *vs.* 2.6%; *P* = 0.01) was significantly elevated in children with HM. These data are shown in [Table 3](#tab03){ref-type="table"}. Table 3.Epidemiological and clinical characteristics of 210 episodes of bloodstream infection stratified by type of paediatric cancerCharacteristics, *n* (%)^a^Solid tumour (*n* = 153)Haematological malignancy (*n* = 57)*P* valueType of infectionLaboratory-confirmed/primary BSI130 (84.9)51 (89.5)0.50Central line-associated BSI120 (78.4)42 (73.7)0.46Permanent central line81 (52.9)36 (63.1)0.21Tunnelled catheter34 (22.2)34 (59.6)\<0.01Implanted catheter47 (30.7)2 (3.5)\<0.01Temporary central line39 (25.5)6 (10.5)0.02Mucosal barrier injury4 (2.6)7 (12.3)0.01Others6 (3.9)2 (3.5)0.99Secondary to23 (15.0)6 (17.5)0.50Gastrointestinal system infection5 (3.2)1 (1.7)0.99Lower respiratory system infection7 (4.6)3 (5.3)0.99Urinary system infection7 (4.6)00.19Others4 (2.6)2 (3.5)0.66Antimicrobial treatment of BSI148 (96.7)57 (100.0)0.32Combination antibiotics in empirical therapy61 (39.9)17 (29.8)0.2Days from BSI to antibiotic beginning, median (range)0 (0--9)0 (0--3)0.97Appropriate empirical therapy96 (62.7)37 (64.9)0.87Antimicrobial de-escalation33 (21.6)11 (19.3)0.84Antimicrobial during empirical therapyCefepime70 (45.8)31 (54.4)0.28Vancomycin60 (39.2)15 (26.3)0.1Meropenem20 (13.1)15 (26.3)0.04Ceftriaxone16 (10.5)5 (8.8)0.8Fluconazole7 (4.6)00.19Combination of antibiotic during empirical therapyCefepime plus vancomycin32 (20.9)9 (15.8)0.44Meropenem plus vancomycin10 (6.5)5 (8.8)0.55Cefepime plus linezolid2 (1.3)2 (3.5)0.29C-reactive protein (mg/dL), median (range)4.6 (0.0--50.1)5.4 (0.0--50.0)0.73C-reactive protein \>5.0 mg/dL68 (44.4)24 (42.1)0.87Indication for intensive care36 (23.5)6 (10.5)0.05Clinical outcome within 30 days after BSIOverall death25 (16.3)4 (7.0)0.11Death in 7 days6 (3.9)2 (3.5)0.99LOS after BSI, median in days (range)13 (0--88)19 (2--56)0.02LOS attributable to BSI, median in days (range)9 (0--65)8 (1--41)0.89[^8][^9][^10]

Outcome, severity and treatment of BSI episodes {#sec4-3}
-----------------------------------------------

The 30-day (late) and 7-day (early) mortalities were 13.8% and 3.8%, respectively. Late and early mortalities were similar among patients with ST and HM. Indication for intensive care was significantly higher in children with ST than with HM (23.5% *vs.* 10.5%; *P* = 0.05) and length of hospital stay after BSI was significantly higher in children with HM than with ST (median of 19 *vs.* 13 days; *P* = 0.02). Most (97.6%) of the BSI episodes were treated with antibiotics; 62.7% of these treatments were empirically appropriate, as shown in [Table 3](#tab03){ref-type="table"}.

Microbiological profile {#sec4-4}
-----------------------

Almost half (44.3%) of the BSI was caused by Gram-positive cocci (GPC), of which 15.7% was coagulase-negative *Staphylococci* and 12.8% was *S. aureus*. Among BSI episodes caused by Gram-negative bacilli (GNB, 40.5%), *Klebsiella pneumoniae* (10%) and *Pseudomonas aeruginosa* (6.7%) were the most frequent bacteria identified. The proportion of BSI caused by GNB (35.9% *vs.* 52.6%; *P* = 0.04) and polymicrobial BSI (5.9% *vs.* 15.8%; *P* = 0.05) was significantly higher in children with HM than children with ST. Specifically, the frequency of polymicrobial infection caused by GPC plus fungus was elevated in those with HM (0% *vs.* 7.0%; *P* *\<* 0.01). Forty-four (20.9%) BSI episodes were caused by antimicrobial-resistant microorganisms, mostly EGNB resistant to third or fourth generation cephalosporins (13.3%). The proportion of BSI due to antimicrobial-resistant pathogens was similar in children with ST and HM, as seen in [Table 4](#tab04){ref-type="table"}. Table 4.Microbiological profile of 210 episodes of bloodstream infection stratified by type of paediatric cancerMicroorganism, *n* (%)Solid tumour (*n* = 153)Haematological malignancy (*n* = 57)*P* valueGram-positive cocci74 (48.4)19 (33.3)0.06Coagulase-negative *Staphylococci*25 (16.3)8 (14.0)0.83*Staphylococcus aureus*23 (15.0)4 (7.0)0.16*Streptococcus* spp.7 (4.6)4 (7.0)0.49Others^a^19 (25.7)3 (15.7)0.20Gram-negative bacilli55 (35.9)30 (52.6)0.04*Klebsiella pneumoniae*14 (9.2)7 (12.3)0.60*Pseudomonas aeruginosa*10 (6.5)4 (7.0)0.99*Escherichia coli*7 (4.6)6 (10.5)0.12*Enterobacter cloacae*9 (5.9)2 (3.5)0.73Others^b^15 (27.2)11 (36.7)0.10Fungus28 (18.3)13 (22.8)0.43*Candida* spp.17 (11.1)6 (10.5)0.99Other yeasts5 (3.3)4 (7.0)0.26Filamentous6 (3.9)3 (5.3)0.71Polymicrobial9 (5.9)9 (15.8)0.05GPC plus fungus04 (7.0)\<0.01Others9 (5.9)5 (8.8)0.53Antimicrobial-resistant pathogen31 (20.3)13 (22.8)0.7Methicillin-resistant *S. aureus*9 (5.9)2 (3.5)0.73Penicillin-resistant *Streptococcus* spp.4 (2.6)00.57GNB resistant to 3rd/4th GC20 (13.1)8 (14)0.82Carbapenem-resistant non-fermentative GNB1 (0.7)2 (3.5)0.17[^11][^12][^13]

Discussion {#sec5}
==========

In this study, epidemiological, clinical and microbiological characteristics among children with HM and ST complicated by BSI were compared and significant differences were found in these two groups. Most of the patients included in the study used first-line chemotherapy treatment for their cancer and had the possibility of cure. This is the second study comparing these characteristics in children with HM and ST complicated by BSI worldwide \[[@ref4]\].

The patients\' physical status characteristics and immunological conditions were associated with the type of cancer the patients had. The frequency of confinement to bed at the moment of BSI, as well as mechanical ventilation and surgical procedures within 30 days before BSI, were significantly higher in children with ST than with HM. In contrast, the presence of neutropenia, mucositis and corticosteroid use during the BSI, and the use of antibiotics 30 days before the BSI were significantly higher in patients with HM than with ST. These potential predisposing characteristics might be investigated by using an appropriate study designed to identify risk factors for BSI in children, according to their type of cancer.

The most common type of infection identified in both groups of patients was LCBI, totalling more than 80% of the BSI episodes in each group. In particular, CLABSI with a temporary central line and implanted catheter was identified in children with ST, and tunnelled catheter-associated BSI was detected in those with HM. This finding is most likely due to differences in the distribution of these line-types between the two cancer groups. There were only 2.6% of the frequencies of MBIBSI in this cohort \[[@ref6]\] with a higher proportion of MBIBSI occurring in children with HM than with ST. This finding can be explained by the lower prevalence of severe neutropenia and mucositis observed in children with ST. The occurrence of BSI caused by GNB and polymicrobial infections, mainly due to GPC plus fungus, was significantly higher in children with HM than with ST. These findings can be explained by the higher frequency of specific factors for BSI acquisition in this group of patients, such as neutropenia and mucositis. Neutropenia was already associated with bacterial invasive disease in children with neoplastic diseases \[[@ref13]\]. Additionally, damage to the gastrointestinal mucosa allows different species of microorganisms colonizing this body site to reach the bloodstream and cause BSI. In fact, the frequency of MBIBSI was significantly higher in children with HM, which can be explained by the elevated frequency of neutropenia and mucositis in these patients.

Severe BSI episodes requiring intensive care were more frequent among children with ST. However, late and early mortalities were similar in patients with HM and ST. This finding is different from that described in a previous study comparing these two groups of cancer complicated by BSI in children conducted in Egypt in 2005, which showed a trend towards higher severity and mortality among those with HM \[[@ref4]\]. This tendency of higher BSI severity among patients with ST could be explained by the presence of a lower level of cellular and humoral immunosuppression in comparison to patients with HM \[[@ref14]\]. Consequently, children with ST might have a more pronounced inflammatory response to infectious antigens during a more severe illness than those with HM. Surprisingly, the mortality was similar in these groups of patients with different BSI severity. This finding could be due to spontaneous matching in the disease status, the focus of BSI and the adequacy of antimicrobial therapy among the patients with HM and ST included in this cohort study.

A very high proportion of antibiotic combination including vancomycin during empirical therapy was observed in both groups of patients. This finding can be related to the elevated frequency of CLABSI occurrence in these individuals leading to a high likelihood of BSI caused by GPC, including MRSA. However, the length of hospital stay after BSI was significantly higher in children with HM, possibly due to specific clinical characteristics that prevent discharge, such as neutropenia and mucositis.

In conclusion, this study found relevant differences in BSI presentation among paediatric patients with HM and ST. These findings suggest that predisposing characteristics of BSI acquisition and death associated with BSI can be cancer-specific. These specific factors should be investigated in a study designed to include appropriate control groups of children without BSI and that survived after BSI acquisition, respectively.

We would like to express our thanks towards the team of Infection Control Section and Clinical Microbiology Laboratory of Hospital do Câncer I of Instituto Nacional do Câncer, Elsie Storch Borges, Ana Paula Siqueira, Eduardo Duarte Velasco, Vania Maria Gonçalves and Silvana Vargas Superti

Conflict of interest {#nts2}
====================

None.

This research received no specific grant from any funding agency, commercial or not-for-profit sectors.

[^1]: ^a^Except when indicated beside the variable.

[^2]: ^b^Were defined as census tracts with at least 51 houses on illegally occupied land, with construction outside of existing municipal patterns or non-secure access to essential public services \[[@ref10]\].

[^3]: ^c^Neutropenia was defined as ANC \<0.5  × 109/L \[[@ref9]\].

[^4]: ^d^Severe neutropenia as \<0.1  × 109/L or \<0.5  × 109/L for more than 7 days \[[@ref9]\].

[^5]: BSI, bloodstream infection.

[^6]: ^a^Primitive neuroectodermal tumour.

[^7]: ^b^Solid tumours with less than five cases.

[^8]: ^a^Except when indicated beside the variable.

[^9]: ^b^Inpatient days with antibiotics after BSI episode has been diagnosed.

[^10]: BSI, bloodstream infection; LOS, length of hospital stay.

[^11]: ^a^Solid tumour: *Bacillus* spp. (*n* = 4); *Micrococcus* spp. (*n* = 4); *Corynebacterium* spp. (*n* = 4); *Arthrobacter* spp. (*n* = 3); *Enterococcus faecium* (*n* = 3); *Leifsonia aquatica* (*n* = 1). Haemtological malignancy: *Arthrobacter* spp. (*n* = 1); *Corynebacterium* spp. (*n* = 1); *Enterococcus faecium* (*n* = 1).

[^12]: ^b^Solid tumour: *Serratia marcescens* (*n* = 2); *Pantoea* spp. (*n* = 2); *Comamonas testosteroni* (*n* = 2); *Acinetobacter baumannii* (*n* = 1); *Alcaligenes faecalis* (*n* = 1); *Klebsiella oxytoca* (*n* = 1); *Providencia stuartii* (*n* = 1); *Pseudomonas putida* (*n* = 1); *Ralstonea picketii* (*n* = 1); *Stenotrophomonas maltophilia* (*n* = 1); *Sphingomonas paucimobilis* (*n* = 1); *Salmonella* spp. (*n* = 1).

[^13]: GNB, Gram-negative bacilli; GPC, Gram-positive cocci; GC, generation cephalosporin.
